March 19th 2021
By Tony Hagen
Following lackluster experience with biosimilar marketing in the United States, Merck moves forward with spinoff plan.
March 15th 2021
Alvotech closes on $35 million in funding, and Samsung Bioepis gets closer to marketing an adalimumab biosimilar. Alvotech's planned high-tech expansion is pictured.
March 13th 2021
The Senate has passed a bill requiring the FDA to provide educational information that supports and promotes the adoption of biosimilars.
March 6th 2021
Minnesota legislators introduce what could possibly become the first law to curtail payers' rights to determine which biologics patients have access to.
March 3rd 2021
By Skylar Jeremias
Regulatory and launch news on rheumatology biosimilars for adalimumab and infliximab was plentiful in February 2021.
March 2nd 2021
Biocon and Viatris edge closer to EU marketing authorization for a bevacizumab biosimilar, among other biosimilar business developments.
February 27th 2021
By Sarfaraz K. Niazi, PhD
Biosimilars have come a long way, and their path has mirrored that of generics—fraught with obstacles. Still, a stronger embrace is needed from physicians and payers.
February 22nd 2021
Gary H. Lyman, MD, PhD, provides an expert overview on overcoming the challenges of discussing biosimilars with patients.
February 17th 2021
Coherus BioSciences filed a 351(k) biologics license application (BLA) for CHS-1420, an adalimumab biosimilar candidate.
February 16th 2021
The launch of Hyrimoz gives Sandoz 5 biosimilars on the Canadian market. National policies on switching have given biosimilars a tailwind.
